Search
Regenxbio Inc
RGNXAdd to Watchlist
9.615USD
+0.015+0.16%
Close 07-29 16:00（ET）Quotes delayed by 15 min
489.33MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-29The current earnings forecast score of Regenxbio Inc is 8.46, ranking 120 out of 384 in the Biotechnology & Medical Research industry. The average price target is 34.00, with a high of 52.00 and a low of 14.00.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
26.000
Target Price
+167.77%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Regenxbio Inc
RGNX
13
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Regenxbio Inc's expected revenue for the next quarter?
Regenxbio Inc's expected revenue is 119.09M.
What is Regenxbio Inc's price target?
Analysts forecast that Regenxbio Inc's price target is USD 34.00, with the highest forecast at USD 52.00 and the lowest forecast at USD 14.00.
How have Regenxbio IncRGNX's recent earnings per share performed?
The market expectation was USD -1.72, while Regenxbio IncRGNX's earnings per share (EPS) for the previous quarter was USD -1.30. EPS for the next quarter is expected at USD 0.22.
What is the analyst rating for Regenxbio Inc?
Based on the ratings of Regenxbio Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.